Table 1 Baseline demographic and clinical features of patients with lymphangioleiomyomatosis
From: Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis
Demographics | Numbers | Percentage or value |
|---|---|---|
Total sample size | 142 | 100% |
Age (years) | 38 ± 9 | |
Sex | ||
Female | 142 | 100% |
Former smoker | 0 | 0% |
Complications | ||
Renal angiomyolipomas | 33/142 | 23.2% |
Pneumothorax | 40/142 | 28.2% |
Chylothorax | 48/142 | 33.8% |
Chyloperitoneum | 16/142 | 11.3% |
CT gradinga | ||
I | 7/142 | 4.9% |
II | 9/142 | 6.3% |
III | 119/142 | 83.8% |
Pulmonary function | ||
FEV1 (ml) | 114 | 1622 ± 712 |
FVC (ml) | 114 | 2760 ± 645 |
FEV1% pred | 114 | 58.5 ± 25 |
FVC% pred | 114 | 85 ± 20.6 |
FEV1/FVC (%) | 114 | 57.5 ± 17.9 |
RV% pred | 107 | 161.3 ± 79.3 |
TLC% pred | 107 | 116.8 ± 103.8 |
RV/TLC (%) | 107 | 46.25 ± 13.67 |
DLCO% pred (N = 107) | 107 | 40.7 ± 21.2 |
Arterial blood gas analysis | ||
PaO2 (mmHg) | 122 | 72.3 ± 13.4 |
P(A-a)O2 (mmHg) | 114 | 43.4 ± 51.1 |
Borg dyspnea index | 132 | 2.5 ± 2.1 |
6MWD (m) | 133 | 422 ± 113 |
SGRQ | 132 | |
Symptoms score | 132 | 40.4 ± 24.2 |
Activity score | 132 | 54.2 ± 24.9 |
Impacts score | 132 | 40.5 ± 25.8 |
Total score | 132 | 44.8 ± 23.5 |
Serum VEGF-D level (pg/ml) | 140 | 3318 ± 2578 |